^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

LAMP1 (Lysosomal Associated Membrane Protein 1)

i
Other names: Lysosomal Associated Membrane Protein 1, Lysosome-Associated Membrane Glycoprotein 1, Lysosome-Associated Membrane Protein 1, CD107 Antigen-Like Family Member A, CD107a, LAMP-1, Lysosomal-Associated Membrane Protein 1, CD107a Antigen, LGP120, LAMPA, LAMP1
6d
Targeted introduction of T cell receptor genes at the TRAC locus in cytotoxic T lymphocytes regenerated from human iPSCs by genome editing. (PubMed, Biochem Biophys Res Commun)
Moreover, they produced IFN-γ and upregulated the degranulation marker CD107a in an antigen-specific manner, and exhibited strong cytotoxic activity against target cells expressing the cognate peptide. Collectively, these results provide the first demonstration, to our knowledge, that successful TCR replacement was achieved in iPSC-derived CTLs via genome editing and that the introduced TCRs are functionally competent.
Journal • IO biomarker
|
IFNG (Interferon, gamma) • LAMP1 (Lysosomal Associated Membrane Protein 1)
9d
Targeting LAPTM5 enhances AML sensitivity to cytarabine through autophagy inhibition. (PubMed, Cell Death Dis)
This facilitates autophagolysosome formation and enhances autophagic flux to reduce AraC-induced apoptosis, resulting in drug resistance. Targeting LAPTM5 represents a promising strategy to overcome this autophagy-mediated resistance.
Journal
|
LAMP1 (Lysosomal Associated Membrane Protein 1) • LAMP2 (Lysosomal Associated Membrane Protein 2) • LAPTM5 (Lysosomal Protein Transmembrane 5)
|
cytarabine
9d
Baicalin chemosensitivity enhancement of cisplatin in bladder cancer via autophagy flux inhibition. (PubMed, Front Pharmacol)
Baicalin enhanced the sensitivity of BC cells to cisplatin by inhibiting autophagic flux through lysosomal activity suppression. This study provides a potential botanical drug candidate for chemosensitization during BC chemotherapy.
Journal
|
LAMP1 (Lysosomal Associated Membrane Protein 1) • CTSD (Cathepsin D) • LAMP2 (Lysosomal Associated Membrane Protein 2)
|
cisplatin
15d
Identification and Validation of a Novel Theranostic Target in Triple Negative Breast Cancer with Transcriptomics and Protein Analyses. (PubMed, Breast Cancer (Dove Med Press))
In conclusion, this study suggests LY6E as a potential target for the selective imaging and therapy of TNBC, identified by transcriptomics analysis and cell line experiments. It lays the groundwork to augment clinical impact of future preclinical studies for the development of diagnostic and treatment approaches for TNBC.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • CD74 (CD74 Molecule) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • LAMP1 (Lysosomal Associated Membrane Protein 1) • HLA-DRA (Major Histocompatibility Complex, Class II, DR Alpha) • LY6E (Lymphocyte Antigen 6 Family Member E)
21d
Intratumoral PD-1-directed IL-2 expression via oncolytic vaccinia virus elicits superior antitumor effects with enhanced safety. (PubMed, J Immunother Cancer)
Our findings suggest that PD-1-directed IL-2 delivered via oVV is both safe and effective, making it a promising candidate for clinical translation.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • IL2 (Interleukin 2) • LAMP1 (Lysosomal Associated Membrane Protein 1) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • GZMB (Granzyme B)
21d
Molecular immune signature identifies microglia and NK cell infiltration as a favorable prognostic marker in adult-type high-grade glioma. (PubMed, ESMO Open)
These integrated findings underscore the beneficial immune microenvironment in LTS HGG driven by specific innate and adaptive immune components. This immune signature may serve as a prognostic indicator and guide immunomodulatory therapeutic strategies for gliomas.
Journal
|
CD123 (Interleukin 3 Receptor Subunit Alpha) • LAMP1 (Lysosomal Associated Membrane Protein 1) • HLA-DQA1 (Major Histocompatibility Complex, Class II, DQ Alpha 1) • IL3RA (Interleukin 3 Receptor Subunit Alpha) • NOS2 (Nitric Oxide Synthase 2)
24d
Extracellular amyloid-β42 oligomers alter endo-lysosomal trafficking of Rab7- and Lamp-1-coated vesicles in cultured neuroblastoma cells. (PubMed, J Alzheimers Dis)
In vivo evaluation showed a delayed degradation of endocytosed fluorescent transferrin after incubation with Aβ42 oligomers.ConclusionsAβ42 oligomers may contribute to neuronal toxicity by inducing changes in the identity, distribution and balance of vesicular components associated with the endo-lysosomal pathway. This disruption impacts the processing and degradation of various materials that accumulate in the cytoplasm.
Journal
|
LAMP1 (Lysosomal Associated Membrane Protein 1)
25d
Autophagy is essential for survival and function of polyploid giant cancer cells under therapeutic stress. (PubMed, Cancer Lett)
Here, we investigated the role of autophagy in paclitaxel (PTX)-induced PGCC survival, nuclear maintenance, and migration...PGCCs also displayed a dispersed vimentin intermediate filament network that scaffolded autophagic structures; autophagy inhibition impaired migration in PGCC-derived daughter cells. These findings identify autophagy as a critical process sustaining PGCC survival, structural integrity, and motility, and suggest that targeting autophagy may disrupt PGCC-driven recurrence in aggressive cancers.
Journal
|
SQSTM1 (Sequestosome 1) • LAMP1 (Lysosomal Associated Membrane Protein 1) • VIM (Vimentin) • SOD2 (Superoxide Dismutase 2)
|
paclitaxel
29d
Oleanolic acid-chitosan compound inhibits mitochondrial autophagy and malignant transformation of lung cancer through the PTEN/AKT pathway. (PubMed, Turk J Med Sci)
Cells were pretreated with chloroquine before OAC treatment...OAC effectively inhibits cell proliferation and induces apoptosis and autophagy in A549 cells, with PTEN playing a regulatory role in these processes. These findings suggest that OAC may serve as a potential therapeutic agent for cancer treatment.
Journal • PARP Biomarker • IO biomarker
|
PTEN (Phosphatase and tensin homolog) • BCL2 (B-cell CLL/lymphoma 2) • SQSTM1 (Sequestosome 1) • CASP3 (Caspase 3) • LAMP1 (Lysosomal Associated Membrane Protein 1) • CASP9 (Caspase 9) • ATG5 (Autophagy Related 5) • ANXA5 (Annexin A5) • BECN1 (Beclin 1)
|
chloroquine phosphate
30d
Loss of DDI2 rewires proteostasis through CCN1-driven compensatory autophagy. (PubMed, iScience)
Loss of DDI2 also impairs CCN1-LAMP1 colocalization, suggesting that DDI2 functions as a selective cargo receptor linking the UPS and ALP. These findings reveal a stress-responsive DDI2-CCN1 axis that reshapes proteostasis and highlight DDI2 as a potential therapeutic vulnerability in proteasome-dependent cancers.
Journal
|
LAMP1 (Lysosomal Associated Membrane Protein 1) • CCN1 (Cellular Communication Network Factor 1)
1m
Silencing fatty acid binding protein 5 inhibits prostaglandin E2 and activates CD8 T cells in castration-resistant prostate cancer. (PubMed, Reprod Biol)
In vivo, FABP5 depletion suppressed tumor growth, promoted CD8+ T cell differentiation, and reduced PGE2, mPGES-1, PD-L1, and PCNA expression in tumor tissues. Collectively, these findings demonstrate that FABP5 depletion inhibits PCa proliferation and alleviates immune suppression by activating CD8+ T cells, highlighting FABP5 as a potential therapeutic target for CRPC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • LAMP1 (Lysosomal Associated Membrane Protein 1) • GZMB (Granzyme B) • PCNA (Proliferating cell nuclear antigen) • FABP5 (Fatty Acid Binding Protein 5)
|
PD-L1 expression
1m
Deep learning model and omics screening highlight angiotensinogen as a 5-methylcytosine (m5C) regulated mediator of tumor-microenvironment communication in liver cancer. (PubMed, Front Immunol)
Liver cancer patients with low NSUN2 and high AGT exhibited significantly improved overall survival rates and higher immune infiltration. This study unveils novel regulatory function of m5C-modified AGT in modulating the liver TME that could be helpful for improving liver cancer prognosis and immunotherapy.
Journal • IO biomarker
|
IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • LAMP1 (Lysosomal Associated Membrane Protein 1)